Psychosis Risk and Development: What Do We Know From Population-Based Studies?

被引:23
|
作者
Mennigen, Eva [1 ,4 ]
Bearden, Carrie E. [1 ,2 ,3 ]
机构
[1] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA
[4] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Univ Hosp Carl Gustav Carus, Dresden, Germany
关键词
Adolescence; Neuroimaging; Psychopathology; Psychotic symptoms; Risk factors; Youth; ULTRA-HIGH-RISK; PHILADELPHIA NEURODEVELOPMENTAL COHORT; CLINICAL HIGH-RISK; 22Q11.2 DELETION SYNDROME; TWINS EARLY DEVELOPMENT; MENTAL-HEALTH SURVEY; EARLY-LIFE ADVERSITY; EARLY INTERVENTION; PSYCHIATRIC-SYMPTOMS; GENERAL-POPULATION;
D O I
10.1016/j.biopsych.2019.12.014
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent years have seen an advent in population-based studies in children, adolescents, and adults that examine the prevalence, etiology, and developmental trajectories of diverse subclinical psychopathological symptoms that pose a risk for the later development of severe mental illnesses. It is increasingly recognized that most categorically defined psychiatric disorders occur on a spectrum or continuum, show high heterogeneity and symptom overlap, and share genetic and environmental risk factors. We discuss neurodevelopmental underpinnings of psychosis spectrum symptoms and review brain morphometric and functional alterations as well as genetic liability for psychosis in individuals experiencing psychotic symptoms (PSs) in the general population. With regard to brain structure and function, findings of qualitatively similar alterations in individuals experiencing subthreshold PSs and individuals with overt psychotic disorders support the notion of a psychosis continuum. However, genetic and epidemiological studies have emphasized the overlap of PSs and other psychiatric illnesses. In particular, PSs during adolescence appear to be a nonspecific precursor of different psychopathological outcomes. Given the evidence presented in this review, we argue that findings from population-based studies are appropriate to guide policy-making to further emphasize public health efforts. Broadly accessible mental health programs are promising to make a difference in the field of adolescent mental health. However, the specific efficacy of these programs warrants further study, and caution is advised to not overpathologize potentially transient occurrence of mental health problems.
引用
收藏
页码:315 / 325
页数:11
相关论文
共 50 条
  • [1] Cannabis and psychosis: what do we know and what should we do?
    Colizzi, Marco
    Murray, Robin
    BRITISH JOURNAL OF PSYCHIATRY, 2018, 212 (04) : 195 - 196
  • [2] Psychosis and substances use; what do we know?
    Alharbi, F. F.
    EUROPEAN PSYCHIATRY, 2019, 56 : S349 - S349
  • [3] Genes for psychosis: What do we know, what does it mean?
    Harrison, P. J.
    SCHIZOPHRENIA RESEARCH, 2006, 86 : S1 - S1
  • [4] What do people know about their electrocardiogram?: Results from a population-based study
    Perz, S
    Kuch, B
    Mielck, A
    Döring, A
    Englmeier, KH
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2002, 12 (04): : 88 - 88
  • [5] The risk of viral transmission in feed: What do we know, what do we do?
    Dee, Scott A.
    Niederwerder, Megan C.
    Patterson, Gil
    Cochrane, Roger
    Jones, Cassie
    Diel, Diego
    Brockhoff, Egan
    Nelson, Eric
    Spronk, Gordon
    Sundberg, Paul
    TRANSBOUNDARY AND EMERGING DISEASES, 2020, 67 (06) : 2365 - 2371
  • [6] What we know and what we do not know
    McDonald, JC
    RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [7] We do not know what we do not know
    Spaeth, GL
    OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
  • [8] We know what they think, but do we know what they do?
    Callingham, M
    Baker, T
    INTERNATIONAL JOURNAL OF MARKET RESEARCH, 2002, 44 (03) : 299 - 335
  • [9] What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 : 252 - 254
  • [10] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254